|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:alsoKnownAs
|
gptkb:Stenabolic
|
|
gptkbp:application
|
research chemical
potential treatment for metabolic and cardiovascular diseases
|
|
gptkbp:CASNumber
|
1379686-30-2
|
|
gptkbp:category
|
research chemical
performance-enhancing drug (investigational)
phenylpropanoids
synthetic ligand
|
|
gptkbp:chemspiderID
|
29341913
|
|
gptkbp:developedBy
|
gptkb:The_Scripps_Research_Institute
|
|
gptkbp:discoveredIn
|
2012
|
|
gptkbp:effect
|
alters circadian rhythm
increases exercise endurance in mice
reduces fat mass in animal studies
|
|
gptkbp:hasMolecularFormula
|
C20H24ClN3O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SR 90001
|
|
gptkbp:IUPACName
|
(E)-N-(4-chlorobenzyl)-3-((2,5-dimethylphenoxy)methyl)-4-((methylsulfonyl)amino)benzamide
|
|
gptkbp:legalStatus
|
not approved for human use
|
|
gptkbp:mechanismOfAction
|
REV-ERB agonist
|
|
gptkbp:molecularWeight
|
437.94 g/mol
|
|
gptkbp:pubchemCID
|
49853714
|
|
gptkbp:routeOfAdministration
|
oral (in animal studies)
|
|
gptkbp:synonym
|
gptkb:REV-ERB_agonist_SR9001
|
|
gptkbp:target
|
gptkb:REV-ERBα
gptkb:REV-ERBβ
|
|
gptkbp:bfsParent
|
gptkb:SR_90001_(Virginia)
|
|
gptkbp:bfsLayer
|
7
|